Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
111In-DTPA-exendine-4 PET/CT in patients with adult hyperinsulinism
2015-003317-22Phase 2Active
- Sponsor
- CHU de Lille
- Start
- Feb 2017
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of 111In-DTPA-exendin-4 in hyperinsulinism (HI) (2 arms), sponsored by CHU de Lille. Started Feb 2017; status: active.
02
Drugs
111In-DTPA-exendin-4
03
Conditions
hyperinsulinism (HI)
Beyond the preview
Go deeper on 2015-003317-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003317-22.